Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen.

Neprilysin (NEP) is an endogenous protease that degrades a wide range of peptides including amyloid beta (Aβ), the main pathological component of Alzheimer's disease (AD). We have engineered NEP as a potential therapeutic for AD but found in pre-clinical safety testing that this variant increas...

Full description

Bibliographic Details
Main Authors: Matthew Burrell, Simon J Henderson, Anna Ravnefjord, Fritz Schweikart, Susan B Fowler, Susanne Witt, Kenny M Hansson, Carl I Webster
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4954676?pdf=render
id doaj-e66447b42ce24666aee4005e9eeeb96b
record_format Article
spelling doaj-e66447b42ce24666aee4005e9eeeb96b2020-11-25T02:27:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01117e015811410.1371/journal.pone.0158114Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen.Matthew BurrellSimon J HendersonAnna RavnefjordFritz SchweikartSusan B FowlerSusanne WittKenny M HanssonCarl I WebsterNeprilysin (NEP) is an endogenous protease that degrades a wide range of peptides including amyloid beta (Aβ), the main pathological component of Alzheimer's disease (AD). We have engineered NEP as a potential therapeutic for AD but found in pre-clinical safety testing that this variant increased prothrombin time (PT) and activated partial thromboplastin time (APTT). The objective of the current study was to investigate the effect of wild type NEP and the engineered variant on coagulation and define the mechanism by which this effect is mediated. PT and APTT were measured in cynomolgus monkeys and rats dosed with a human serum albumin fusion with an engineered variant of NEP (HSA-NEPv) as well as in control plasma spiked with wild type or variant enzyme. The coagulation factor targeted by NEP was determined using in vitro prothrombinase, calibrated automated thrombogram (CAT) and fibrin formation assays as well as N-terminal sequencing of fibrinogen treated with the enzyme. We demonstrate that HSA-NEP wild type and HSA-NEPv unexpectedly impaired coagulation, increasing PT and APTT in plasma samples and abolishing fibrin formation from fibrinogen. This effect was mediated through cleavage of the N-termini of the Aα- and Bβ-chains of fibrinogen thereby significantly impairing initiation of fibrin formation by thrombin. Fibrinogen has therefore been identified for the first time as a substrate for NEP wild type suggesting that the enzyme may have a role in regulating fibrin formation. Reductions in NEP levels observed in AD and cerebral amyloid angiopathy may contribute to neurovascular degeneration observed in these conditions.http://europepmc.org/articles/PMC4954676?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Matthew Burrell
Simon J Henderson
Anna Ravnefjord
Fritz Schweikart
Susan B Fowler
Susanne Witt
Kenny M Hansson
Carl I Webster
spellingShingle Matthew Burrell
Simon J Henderson
Anna Ravnefjord
Fritz Schweikart
Susan B Fowler
Susanne Witt
Kenny M Hansson
Carl I Webster
Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen.
PLoS ONE
author_facet Matthew Burrell
Simon J Henderson
Anna Ravnefjord
Fritz Schweikart
Susan B Fowler
Susanne Witt
Kenny M Hansson
Carl I Webster
author_sort Matthew Burrell
title Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen.
title_short Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen.
title_full Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen.
title_fullStr Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen.
title_full_unstemmed Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen.
title_sort neprilysin inhibits coagulation through proteolytic inactivation of fibrinogen.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2016-01-01
description Neprilysin (NEP) is an endogenous protease that degrades a wide range of peptides including amyloid beta (Aβ), the main pathological component of Alzheimer's disease (AD). We have engineered NEP as a potential therapeutic for AD but found in pre-clinical safety testing that this variant increased prothrombin time (PT) and activated partial thromboplastin time (APTT). The objective of the current study was to investigate the effect of wild type NEP and the engineered variant on coagulation and define the mechanism by which this effect is mediated. PT and APTT were measured in cynomolgus monkeys and rats dosed with a human serum albumin fusion with an engineered variant of NEP (HSA-NEPv) as well as in control plasma spiked with wild type or variant enzyme. The coagulation factor targeted by NEP was determined using in vitro prothrombinase, calibrated automated thrombogram (CAT) and fibrin formation assays as well as N-terminal sequencing of fibrinogen treated with the enzyme. We demonstrate that HSA-NEP wild type and HSA-NEPv unexpectedly impaired coagulation, increasing PT and APTT in plasma samples and abolishing fibrin formation from fibrinogen. This effect was mediated through cleavage of the N-termini of the Aα- and Bβ-chains of fibrinogen thereby significantly impairing initiation of fibrin formation by thrombin. Fibrinogen has therefore been identified for the first time as a substrate for NEP wild type suggesting that the enzyme may have a role in regulating fibrin formation. Reductions in NEP levels observed in AD and cerebral amyloid angiopathy may contribute to neurovascular degeneration observed in these conditions.
url http://europepmc.org/articles/PMC4954676?pdf=render
work_keys_str_mv AT matthewburrell neprilysininhibitscoagulationthroughproteolyticinactivationoffibrinogen
AT simonjhenderson neprilysininhibitscoagulationthroughproteolyticinactivationoffibrinogen
AT annaravnefjord neprilysininhibitscoagulationthroughproteolyticinactivationoffibrinogen
AT fritzschweikart neprilysininhibitscoagulationthroughproteolyticinactivationoffibrinogen
AT susanbfowler neprilysininhibitscoagulationthroughproteolyticinactivationoffibrinogen
AT susannewitt neprilysininhibitscoagulationthroughproteolyticinactivationoffibrinogen
AT kennymhansson neprilysininhibitscoagulationthroughproteolyticinactivationoffibrinogen
AT carliwebster neprilysininhibitscoagulationthroughproteolyticinactivationoffibrinogen
_version_ 1724841483059593216